Tudor Investment Corp
SMMT icon

Tudor Investment Corp’s Summit Therapeutics SMMT Stock Holding History

Tudor Investment Corp’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.3M Sell
384,988
-38,096
-9% -$616K 0.01% 936
2025
Q4 		$7.4M Buy
423,084
+75,843
+22% +$1.43M 0.01% 917
2025
Q3 		$7.17M Buy
+347,241
New +$8.42M 0.01% 954
2023
Q3 		– Sell
-32,103
Closed -$80.6K – 2816
2023
Q2 		$80.6K Buy
32,103
+16,988
+112% +$31K ﹤0.01% 2307
2023
Q1 		$26K Buy
+15,115
New +$41.2K ﹤0.01% 2304

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tudor Investment Corp's SMMT Position: Q1 2026 in Review

Tudor Investment Corp reduced its Summit Therapeutics (SMMT) stake by 9% in Q1 2026, selling an estimated $616K and leaving 384,988 shares worth $7.3M. The position accounts for 0.01% of the portfolio, ranked #936.

Tudor Investment Corp first reported a position in SMMT in Q1 2023 and has held it in 5 quarters since. The position peaked at $7.4M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Tudor Investment Corp held 384,988 shares of Summit Therapeutics worth $7.3M as of Q1 2026.
  • Tudor Investment Corp sold 38,096 Summit Therapeutics shares in Q1 2026, an estimated $616K.
  • Summit Therapeutics made up 0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #936 holding.
  • Tudor Investment Corp first reported a position in Summit Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • Tudor Investment Corp's Summit Therapeutics position peaked at $7.4M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.